<DOC>
	<DOCNO>NCT00709995</DOCNO>
	<brief_summary>This study compare effect Enzastaurin plus Sunitinib versus Sunitinib alone metastatic Renal Cell Cancer .</brief_summary>
	<brief_title>A Study Participants With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This multicenter , Phase 2 study enzastaurin sunitinib versus placebo sunitinib first-line therapy participant metastatic renal cell carcinoma , contain 2 part . Part 1 safety lead-in study 12 participant possible dose escalation . Part 2 randomized , double-blind , Phase 2 study 110 participant .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Participants metastatic Renal Cell Carcinoma ( RCC ) receive prior treatment systemic ( adjuvant neoadjuvant ) therapy RCC ( include target therapy tyrosine kinase inhibitor bevacizumab , immunotherapy , chemotherapy , hormonal , investigational therapy ) Histologically confirm RCC metastasis component clear ( conventional ) cell histology Evidence unidimensional measurable disease , measure compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) Primary tumor surgically remove nephrectomy nephronsparing surgery Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Participants must sign informed consent document Have receive prior treatment sunitinib enzastaurin Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Have follow within 12 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure ( CHF ) , cerebrovascular accident , transient ischemic attack , pulmonary embolism Note : Ongoing treatment therapeutic dos Coumadin® ( warfarin ) derivative Coumadin phenprocoumon allow , prophylactic , lowdose Coumadin ( ≤ 2 mg daily ) deep vein thrombosis allow . In case , prothrombin time/international normalization ratio ( PT/INR ) closely monitor clinically indicated Ongoing cardiac arrhythmia &gt; New York Health Association Class II , atrial fibrillation grade , prolongation QTc interval &gt; 450 millisecond ( msec ) males &gt; 470 msec female . Have uncontrolled hypertension [ &gt; 150/100 millimeter mercury ( mm/Hg ) despite optimal medical therapy ] , history poor compliance antihypertensive treatment Require concomitant use potent Cytochrome P450 3A4 ( CYP3A4 ) inducer , example , rifampicin potent CYP3A inhibitor , ketoconazole . Significant surgery radiation therapy &lt; 4 week start study treatment . Prior palliative radiotherapy metastatic lesion ( ) is/are permit , provide least 1 measurable lesion irradiate Participants pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>